SSTR2 (somatostatin receptor 2) is a G-protein coupled receptor that binds somatostatin-14 and -28, mediating inhibitory effects across multiple physiological systems 1. The receptor couples to pertussis toxin-sensitive G proteins to inhibit adenylyl cyclase and suppress voltage-dependent calcium channels, while also activating phosphotyrosine phosphatase through pertussis toxin-insensitive pathways 2. SSTR2 inhibits cell growth and hormone secretion, functioning as the dominant somatostatin receptor in pancreatic endocrine cells and playing a critical role in intestinal T cell progenitor homing during immune development 3. Clinically, SSTR2 is overexpressed in neuroendocrine tumors (gastroenteropancreatic, pituitary, paraganglioma), meningioma, small-cell lung cancer, and select breast cancers 4 5 6. SSTR2-targeted therapies using somatostatin agonists (octreotide) show therapeutic potential: octreotide combined with everolimus demonstrated clinical benefit in recurrent meningiomas 1, while SSTR2 activation decreases osteoclast resorptive activity, suggesting antiosteoporotic applications 7. Pharmacological SSTR2 modulation and receptor-targeted radiopharmaceuticals represent emerging treatment strategies for SSTR2-positive malignancies, with potential enhancement through epigenetic modulation of SSTR2 expression in tumors with low basal receptor levels 6.